LumiThera Introduces the Valeda Light Delivery System
Valeda is the first approved treatment for dry age-related macular degeneration (AMD) using photobiomodulation (PBM). Valeda uses a multi-wavelength approach to stimulate critical targets of cellular function, leading to improved energy production within the mitochondria.
AMD is the leading cause of blindness in adults over 65. Approximately 90% of patients with AMD have the dry form, and 10% have the wet form.
LumiThera is at the forefront of the development of PBM treatments for patients with age-related macular degeneration and other degenerative ocular diseases.